|
1
|
Heinebröring RC, Winkels RM, Renkema JM,
Kragt L, van Orten-Luiten AC, Tigchelaar EF, Chan DS, Norat T and
Kampman E: Dietary supplement use and colorectal cancer risk: A
systematic review and meta-analyses of prospective cohort studies.
Int J Cancer. 136:2388–2401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh
KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, et al: Screening
for gastric cancer in Asia: Current evidence and practice. Lancet
Oncol. 9:279–287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shen W, Li J, Cui J, Xi H, Liu S, Wei B
and Chen L: Meta-analysis of prognosis after surgical treatment in
GC patients with liver metastasis. Zhonghua Wei Chang Wai Ke Za
Zhi. 17:128–132. 2014.(In Chinese). PubMed/NCBI
|
|
5
|
Xu H, Zhang M and Qiao H: Diagnostic
significance of miR-106a in GC. Int J Clin Exp Pathol.
8:13096–13101. 2015.PubMed/NCBI
|
|
6
|
Yoon SK, Yoo C, Ryu MH, Ryoo BY, Chang HM,
Kim TW, Lee JL, Yook JH, Oh ST, Kim BS and Kang YK: 6525 Prognostic
significance of preoperative serum tumor markers in the patients
with curatively resected advanced gastric cancer patients. J Clin
Oncol. 7:3692009.
|
|
7
|
Hasholzner U, Baumgartner L, Stieber P,
Meier W, Reiter W, Pahl H and Fateh-Moghadam A: Clinical
significance of the tumour markers CA 125 II and CA 72-4 in ovarian
carcinoma. Int J Cancer. 69:329–334. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miédougé M, Rouzaud P, Salama G, Pujazon
MC, Vincent C, Mauduyt MA, Reyre J, Carles P and Serre G:
Evaluation of seven tumour markers in pleural fluid for the
diagnosis of malignant effusions. Br J Cancer. 81:1059–1065. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo G, Liu C, Guo M, Cheng H, Lu Y, Jin K,
Liu L, Long J, Xu J, Lu R, et al: Potential biomarkers in lewis
negative patients with pancreatic cancer. Ann Surg. 265:800–805.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bian Y, Wang Z, Xu J, Zhao W, Cao H and
Zhang Z: Elevated Rictor expression is associated with tumor
progression and poor prognosis in patients with gastric cancer.
Biochem Biophys Res Commun. 464:534–540. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gui C, Min L, Jun W, Ji M, Fang C, Shi H,
Zhu D, Chen L, Zhao J, Shi L, et al: Expression of Tim-3 in gastric
cancer tissue and its relationship with prognosis. Int J Clin Exp
Pathol. 8:9452–9457. 2015.PubMed/NCBI
|
|
12
|
Jiang W, Jin Z, Zhou F, Cui J and Wang L
and Wang L: High co-expression of Sp1 and HER-2 is correlated with
poor prognosis of gastric cancer patients. Surg Oncol. 24:220–225.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kulasingam V and Diamandis EP: Strategies
for discovering novel cancer biomarkers through utilization of
emerging technologies. Nat Clin Pract Oncol. 5:588–599. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang G, Hu N, Yang HH, Wang L, Su H, Wang
C, Clifford R, Dawsey EM, Li JM, Ding T, et al: Comparison of
global gene expression of gastric cardia and noncardia cancers from
a high-risk population in china. PLoS One. 8:e638262013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li WQ, Hu N, Burton VH, Yang HH, Su H,
Conway CM, Wang L, Wang C, Ding T, Xu Y, et al: PLCE1 mRNA and
protein expression and survival of patients with esophageal
squamous cell carcinoma and gastric adenocarcinoma. Cancer
Epidemiol Biomarkers Prev. 23:1579–1588. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Davis S and Meltzer PS: GEOquery: A bridge
between the gene expression omnibus (GEO) and BioConductor.
Bioinformatics. 23:1846–1847. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and
Lin CY: cytoHubba: Identifying hub objects and sub-networks from
complex interactome. BMC Syst Biol. 8 Suppl 4:S112014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The Gene
Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Minoru K and Susumu G: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 27:27–30.
2000.
|
|
21
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:(Web
Server Issue). W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cao GD, Xu XY, Zhang JW, Chen B and Xiong
MM: Phosphorylated mammalian target of rapamycin p-mTOR is a
favorable prognostic factor than mTOR in gastric cancer. PLoS One.
11:e01680852016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sasako M, Sano T, Yamamoto S, Kurokawa Y,
Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai
K, et al: D2 Lymphadenectomy Alone or with Para-aortic Nodal
Dissection for gastric cancer. N Engl J Med. 359:453–462. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zou WB, Yang F and Li ZS: How to improve
the diagnosis rate of early gastric cancer in China. Zhejiang Da
Xue Xue Bao Yi Xue Ban. 44:9–14. 2015.(In Chinese). PubMed/NCBI
|
|
27
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsai MM, Wang CS, Tsai CY, Huang HW, Chi
HC, Lin YH, Lu PH and Lin KH: Potential diagnostic, prognostic and
therapeutic targets of MicroRNAs in human gastric cancer. Int J Mol
Sci. 17(pii): E9452016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Azarbarzin S, Feizi MAH, Safaralizadeh R,
Kazemzadeh M and Fateh A: The value of MiR-383, an intronic MiRNA,
as a diagnostic and prognostic biomarker in intestinal-type gastric
cancer. Biochem Genet. 55:244–252. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Singh P, Toom S and Huang Y: Anti-claudin
18.2 antibody as new targeted therapy for advanced gastric cancer.
J Hematol Oncol. 10:1052017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen SL, Li JP, Li LF, Zeng T and He X:
Elevated preoperative serum alanine aminotransferase/aspartate
aminotransferase (ALT/AST) ratio is associated with better
prognosis in patients undergoing curative treatment for gastric
adenocarcinoma. Int J Mol Sci. 17(pii): E9112016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Biemer-Hüttmann AE, Walsh MD, McGuckin MA,
Simms LA, Young J, Leggett BA and Jass JR: Mucin core protein
expression in colorectal cancers with high levels of microsatellite
instability indicates a novel pathway of morphogenesis. Clin Cancer
Res. 6:1909–1916. 2000.PubMed/NCBI
|
|
33
|
Kim DH, Kim JW, Cho JH, Baek SH, Kakar S,
Kim GE, Sleisenger MH and Kim YS: Expression of mucin core
proteins, trefoil factors, APC and p21 in subsets of colorectal
polyps and cancers suggests a distinct pathway of pathogenesis of
mucinous carcinoma of the colorectum. Int J Oncol. 27:957–964.
2005.PubMed/NCBI
|
|
34
|
Renaud F, Vincent A, Mariette C, Crépin M,
Stechly L, Truant S, Copin MC, Porchet N, Leteurtre E, Van
Seuningen I and Buisine MP: MUC5AC hypomethylation is a predictor
of microsatellite instability independently of clinical factors
associated with colorectal cancer. Int J Cancer. 136:2811–2821.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Renaud F, Mariette C, Vincent A, Wacrenier
A, Maunoury V, Leclerc J, Coppin L, Crépin M, Van Seuningen I,
Leteurtre E and Buisine MP: The serrated neoplasia pathway of
colorectal tumors: Identification of MUC5AC hypomethylation as an
early marker of polyps with malignant potential. Int J Cancer.
138:1472–1481. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lindén SK, Wickström C, Lindell G,
Gilshenan K and Carlstedt I: Four modes of adhesion are used during
Helicobacter pylori binding to human mucins in the oral and gastric
niches. Helicobacter. 13:81–93. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Van de Bovenkamp JH, Mahdavi J,
Korteland-Van Male AM, Büller HA, Einerhand AW, Borén T and Dekker
J: The MUC5AC glycoprotein is the primary receptor for Helicobacter
pylori in the human stomach. Helicobacter. 8:521–532. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kocer B, Ulas M, Ustundag Y, Erdogan S,
Karabeyoglu M, Yldrm O, Unal B, Cengiz O and Soran A: A
confirmatory report for the close interaction of Helicobacter
pylori with gastric epithelial MUC5AC expression. J Clin
Gastroenterol. 38:496–502. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou CJ, Zhang LW, Gao F, Zhang B, Wang Y,
Chen DF and Jia YB: Association analysis of common genetic
variations in MUC5AC gene with the risk of non-cardia gastric
cancer in a Chinese population. Asian Pac J Cancer Prev.
15:4207–4210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Eom DW, Hong SM, Kim J, Kim G, Bae YK,
Jang KT and Yu E: Notch3 signaling is associated with MUC5AC
expression and favorable prognosis in patients with small
intestinal adenocarcinomas. Pathol Res Pract. 210:501–507. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim SM, Kwon CH, Shin N, Park DY, Moon HJ,
Kim GH and Jeon TY: Decreased Muc5AC expression is associated with
poor prognosis in gastric cancer. Int J Cancer. 134:114–124. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Duval E, Bigot N, Hervieu M, Kou I,
Leclercq S, Galéra P, Boumediene K and Baugé C: Asporin expression
is highly regulated in human chondrocytes. Mol Med. 17:816–823.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Castellana B, Escuin D, Peiró G,
Garcia-Valdecasas B, Vázquez T, Pons C, Pérez-Olabarria M, Barnadas
A and Lerma E: ASPN and GJB2 are implicated in the mechanisms of
invasion of ductal breast carcinomas. J Cancer. 3:175–183. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Turtoi A, Musmeci D, Wang Y, Dumont B,
Somja J, Bevilacqua G, De Pauw E, Delvenne P and Castronovo V:
Identification of novel accessible proteins bearing diagnostic and
therapeutic potential in human pancreatic ductal adenocarcinoma. J
Proteome Res. 10:4302–4313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ding Q, Zhang M and Liu C: Asporin
participates in gastric cancer cell growth and migration by
influencing EGF receptor signaling. Oncol Rep. 33:1783–1790. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ju M, Zhang T, Bai X, Ren X, Li K and Li
G: Analysis of type IV osteogenesis imperfecta caused by two
mutations occurred simultaneously in COL1A1 gene in a Chinese
child. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 33:140–144. 2016.(In
Chinese). PubMed/NCBI
|
|
47
|
Cho SY, Lee JH, Ki CS, Chang MS, Jin DK
and Han HS: Osteogenesis imperfecta Type I caused by a novel
mutation in the start codon of the COL1A1 gene in a Korean family.
Ann Clin Lab Sci. 45:100–105. 2015.PubMed/NCBI
|
|
48
|
McInerney-Leo AM, Duncan EL, Leo PJ,
Gardiner B, Bradbury LA, Harris JE, Clark GR, Brown MA and Zankl A:
COL1A1 C-propeptide cleavage site mutation causes high bone mass,
bone fragility and jaw lesions: A new cause of gnathodiaphyseal
dysplasia? Clin Genet. 88:49–55. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Drew JE, Farquharson AJ, Mayer CD, Vase
HF, Coates PJ, Steele RJ and Carey FA: Predictive gene signatures:
Molecular markers distinguishing colon adenomatous polyp and
carcinoma. PLoS One. 9:e1130712014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hayashi M, Nomoto S, Hishida M, Inokawa Y,
Kanda M, Okamura Y, Nishikawa Y, Tanaka C, Kobayashi D, Yamada S,
et al: Identification of the collagen type 1 α 1 gene (COL1A1) as a
candidate survival-related factor associated with hepatocellular
carcinoma. BMC Cancer. 14:1082014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
He M, Wang Z, Zhao J, Chen Y and Wu Y:
COL1A1 polymorphism is associated with risks of osteosarcoma
susceptibility and death. Tumour Biol. 35:1297–1305. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ouchi K, Miyachi M, Tsuma Y, Tsuchiya K,
Iehara T, Konishi E, Yanagisawa A and Hosoi H: FN1: A novel fusion
partner of ALK in an inflammatory myofibroblastic tumor. Pediatr
Blood Cancer. 62:909–911. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Puls F, Hofvander J, Magnusson L, Nilsson
J, Haywood E, Sumathi VP, Mangham DC, Kindblom LG and Mertens F:
FN1-EGF gene fusions are recurrent in calcifying aponeurotic
fibroma. J Pathol. 238:502–507. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lee JC, Jeng YM, Su SY, Wu CT, Tsai KS,
Lee CH, Lin CY, Carter JM, Huang JW, Chen SH, et al: Identification
of a novel FN1-FGFR1 genetic fusion as a frequent event in
phosphaturic mesenchymal tumour. J Pathol. 235:539–545. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kida H, Takano Y, Yamamoto K, Mori M,
Yanaga K, Tanaka J, Kudo SE and Mimori K: A single nucleotide
polymorphism in fibronectin 1 determines tumor shape in colorectal
cancer. Oncol Rep. 32:548–552. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang Y, Huang L, Wu S, Jia Y, Yang Y, Luo
L, Bi A and Fang M: Bioinformatics analyses of the role of vascular
endothelial growth factor in patients with non-small cell lung
cancer. PLoS One. 10:e01392852015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ma LJ, Lee SW, Lin LC, Chen TJ, Chang IW,
Hsu HP, Chang KY, Huang HY and Li CF: Fibronectin overexpression is
associated with latent membrane protein 1 expression and has
independent prognostic value for nasopharyngeal carcinoma. Tumour
Biol. 35:1703–1712. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Gupta N, Khan R, Kumar R, Kumar L and
Sharma A: Versican and its associated molecules: Potential
diagnostic markers for multiple myeloma. Clin Chim Acta.
442:119–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sluiter N, de Cuba E, Kwakman R, Meijerink
WJ, Delis-van Diemen PM, Coupé VM, Beliën JA, Meijer GA, de Hingh
IH and te Velde EA: Versican and vascular endothelial growth factor
expression levels in peritoneal metastases from colorectal cancer
are associated with survival after cytoreductive surgery and
hyperthermic intraperitoneal chemotherapy. Clin Exp Metastasis.
33:297–307. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yen CY, Huang CY, Hou MF, Yang YH, Chang
CH, Huang HW, Chen CH and Chang HW: Evaluating the performance of
fibronectin 1 (FN1), integrin α4β1 (ITGA4), syndecan-2 (SDC2), and
glycoprotein CD44 as the potential biomarkers of oral squamous cell
carcinoma (OSCC). Biomarkers. 18:63–72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kim NS, Lee HH, Jung CK and Jeon HM:
Versican expression in tumor epithelial cells is correlated with a
good prognosis in gastric cancer. Anticancer Res. 34:5613–5619.
2014.PubMed/NCBI
|
